Dossier assessment
Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children and adolescents (≥ 13 to < 18 years) with relapsing remitting multiple sclerosis who have not yet received disease-modifying therapy, or children and adolescents pretreated with disease-modifying therapy whose disease is not highly active
Hint of non-quantifiable added benefit
Project details
- Project no.
- A23-68
- Commission
- Commission awarded on 06.07.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-68